MedTrace Logo

Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation

NCT01516567 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2026-02-09

No results posted yet for this study

Summary

Phase II trial to determine the efficacy of Dose Adjusted-EPOCH-Rituximab regimen in children and adolescent with primary mediastinal large B cell lymphoma in terms of event free survival.

Conditions

  • Primary Mediastinal Large B Cell Lymphoma

Interventions

DRUG

Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab

6 courses of Dose Adjusted-EPOCH-Rituximab Rituximab 375 mg/m² i.v.: one injection at each of the 6 courses of EPOCH.

Sponsors & Collaborators

  • Children's Oncology Group

    collaborator NETWORK

  • Gustave Roussy, Cancer Campus, Grand Paris

    lead OTHER

Principal Investigators

  • Catherine PATTE, MD · Institut Gustave Roussy, Villejuif, FRANCE

  • Thomas GROSS, MD · Children's Oncology Group, USA

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-01
Primary Completion
2017-04-30
Completion
2022-11-16

Countries

  • Belgium
  • Canada
  • France
  • Hungary
  • Italy
  • Netherlands
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01516567 on ClinicalTrials.gov